Inhibition of β-lactamase function by de novo designed peptide
PLOS ONE · 08.09.2023 · 18 (9) · e0290845
DOI: 10.1371/journal.pone.0290845 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 08.09.2023. Verfasst von Arunima Mishra und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Microbiology & Molecular Genetics, School of Medicine, Loma Linda University, Loma Linda, California, United States America. Hauptthemen laut MEDLINE: beta-Lactamases, beta-Lactamase Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDCR NIH HHS, National Institute of Dental and Craniofacial Research, QuantBioRes-QBR A/S.
Abstract (Originalsprache)
Antimicrobial resistance is a great public health concern that is now described as a “silent pandemic”. The global burden of antimicrobial resistance requires new antibacterial treatments, especially for the most challenging multidrug-resistant bacteria. There are various mechanisms by which bacteria develop antimicrobial resistance including expression of β-lactamase enzymes, overexpression of efflux pumps, reduced cell permeability through downregulation of porins required for β-lactam entry, or modifications in penicillin-binding proteins. Inactivation of the β-lactam antibiotics by β-lactamase enzymes is the most common mechanism of bacterial resistance to these agents. Although several effective small-molecule inhibitors of β-lactamases such as clavulanic acid and avibactam are clinically available, they act only on selected class A, C, and some class D enzymes. Currently, none of the clinically approved inhibitors can effectively inhibit Class B metallo-β-lactamases. Additionally, there is increased resistance to these inhibitors reported in several bacteria. The objective of this study is to use the Resonant Recognition Model (RRM), as a novel strategy to inhibit/modulate specific antimicrobial resistance targets. The RRM is a bio-physical approach that analyzes the distribution of energies of free electrons and posits that there is a significant correlation between the spectra of this energy distribution and related protein biological activity. In this study, we have used the RRM concept to evaluate the structure-function properties of a group of 22 β-lactamase proteins and designed 30-mer peptides with the desired RRM spectral periodicities (frequencies) to function as β-lactamase inhibitors. In contrast to the controls, our results indicate 100% inhibition of the class A β-lactamases from Escherichia coli and Enterobacter cloacae . Taken together, the RRM model can likely be utilized as a promising approach to design β-lactamase inhibitors for any specific class. This may open a new direction to combat antimicrobial resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Microbiology & Molecular Genetics, School of Medicine, Loma Linda University, Loma Linda, California, United States America.
- AMALNA Consulting, Black Rock, Melbourne, VIC, Australia.
- QuantBioRes-QBR A/S, Copenhagen, Denmark.
ORCID-Profile: Arunima Mishra
Förderung
- NIDCR NIH HHS
- National Institute of Dental and Craniofacial Research
- QuantBioRes-QBR A/S
Zitieren
APA
Mishra, A., Cosic, I., Loncarevic, I., Cosic, D., & Fletcher, H. M. (2023). Inhibition of β-lactamase function by de novo designed peptide. PLOS ONE, 18(9), e0290845. https://doi.org/10.1371/journal.pone.0290845
Vancouver
Mishra A, Cosic I, Loncarevic I, Cosic D, Fletcher HM. Inhibition of β-lactamase function by de novo designed peptide. PLOS ONE. 2023;18(9):e0290845. doi:10.1371/journal.pone.0290845
BibTeX
@article{Mishra2023,
author = {Mishra, Arunima and Cosic, Irena and Loncarevic, Ivan and Cosic, Drasko and Fletcher, Hansel M},
title = {Inhibition of β-lactamase function by de novo designed peptide},
journal = {PLOS ONE},
year = {2023},
volume = {18},
number = {9},
pages = {e0290845},
doi = {10.1371/journal.pone.0290845}
}
EUVIMED